Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats

Neuropharmacology

Volumn 35, Issue 1, 1996, Pages 23-28

  Santamaria A ^b   Rios C ^b   Solis Hernandez F ^b   Ordaz Moreno, J ^a,b   Gonzalez Reynoso L ^b   Altagracia, M ^a,b   Kravzov, J ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b NONE

Author keywords

circling behavior; excitotoxicity; GABA; kynurenic acid; kynurenine; NMDA receptor; probenecid; quinolinic acid

Indexed keywords

4 AMINOBUTYRIC ACID; DIZOCILPINE; EXCITOTOXIN; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROBENECID; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; GABAERGIC SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030049004     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/0028-3908(95)00145-X     Document Type: Article

References (48)

1. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J. and Martin J. B. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321: 168-171.
2. Carpenedo R., Chiarugi A., Russi P., Lombardi G., Carla V., Pellicciari R., Mattoli L. and Moroni F. (1994) Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61: 237-244.
3. Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science 262: 689-695.
4. During M. J., Heyes M. P., Freese A., Markey S. P., Martin J. B. and Roth R. H. (1989) Quinolinic acid concentrations in striatal extracellular fluid reach potentially neurotoxic levels following systemic L-tryptophan loading. Brain Res. 476: 384-387.
5. Ferrante R. J., Kowall N. W., Cipolloni P. B., Storey E. and Beal M. F. (1993) Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neur. 119: 46-71.
6. Fleury M. O. and Ashley D. V. (1983) High-performance liquid chromatography analysis of amino acids in physiological fluids: on line precolumn derivatization with o-phthal-dialdehyde. Analyt. Biochem. 133: 330-335.
7. Foster A. C., Collins J. F. and Schwarcz R. (1983) On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 22: 1331-1342.
8. Foster A. C., Vezzani A., French E. D. and Schwarcz R. (1984) Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48: 273-278.
9. Foster, A. C., Gill R. and Woodruff G. N. (1987) MK-801 prevents degeneration of striatal neurones caused by intrastriatal injection of quinolinic acid. Br. J. Pharmac. Proc. Suppl. 90: 7P.
10. Foster A. C., Gill R. and Woodruff G. N. (1988) Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J. Neurosci. 8: 4745-4754.
11. Fukui S., Schwarcz R., Rapoport S. I., Takada Y. and Smith Q. R. (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56: 2007-2017.
12. Giordano M., Ford L. M., Brauckmann J. L., Norman A. B. and Sanberg P. R. (1990) MK801 prevents quinolinic acid-induced behavioral deficits and neurotoxicity in the striatum. Brain Res. Bull. 24: 313-319.
13. Hantraye P., Richie D., Maziere M. and Isacson O. (1990) A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp. Neur. 108: 91-104.
14. Heyes M. P., Mefford I. N., Quearry B. J., Dedhia M. and Lackner A. (1990) Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected Rhesus macaques: relationship to clinical and viral status. Ann. Neur. 27: 666-675.
15. Heyes M. P. and Lackner A. (1990) Increased cerebrospinal fluid quinolinic acid, kynurenic acid and L-kynurenine in acute septicemia. J. Neurochem. 55: 338-341.
16. Heyes M. P., Saito K., Crowley J. S., Davis L. E., Demitrack M. A., Der M., Dilling L. A., Elia J., Kruesi M. J. P., Lackner A., Larsen S. A., Lee K., Leonard H. L., Markey S. P., Martin A., Milstein S., Mouradian M. M., Pranzatelli M. R., Quearry B. J., Salazar A., Smith M., Strauss S. E., Sunderland T., Swedo S. W. and Tourtellotte W. W. (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 115: 1249-1273.
17. Kravzov J., Santamaría A., Ríos C., Flores A. and Altagracia M. (1993) Protective effect of probenecid on circling behavior of rats with unilateral quinolinic acid-induced striatal lesions. Proc. West. Pharmac. Soc. 36: 255-257.
18. Lekieffre D., Plotkine M., Allix M. and Boulu R. G. (1990) Kynurenic acid antagonizes hippocampal quinolinic acid neurotoxicity: behavioral and histological evaluation. Neurosci. Lett. 120: 31-33.
19. Miller J. M., MacGarvey U. and Beal M. F. (1992) The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. Neurosci. Lett. 146: 115-118.
20. Moroni F., Lombardi G., Carla V., Pellegrini D., Carassale G. L. and Cortesini C. (1986) Content of quinolinic acid and of other tryptophan metabolites increases in brain regions of rats used as experimental models of hepatic encephalopathy. J. Neurochem. 46: 869-874.
21. Moroni F., Russi P., Lombardi G., Beni M. and Carla V. (1988) Presence of kynurenic acid in the mammalian brain. J. Neurochem. 51: 177-180.
22. Norman A. B., Wyatt L. M., Hildebrand J. P., Kolmonpunporn M., Moody C. A., Lehman M. N. and Sanber P. R. (1990) Sensitization of rotation behavior in rats with unilateral 6-hydroxydopamine or kainic acid-induced striatal lesions. Pharmac. Biochem. Behav. 37: 755-759.
23. Ogawa T., Matson W. R., Beal M. F., Myers R. H., Bird E. D., Milbury P. and Saso S. (1992) Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42: 1702-1706.
24. Olney J. W., Ikonomidou C., Mosinger J. L. and Friedrich G. (1989a) MK-801 prevents hypobaric-ischemic neuronal degeneration in infant rat brain. J. Neurosci. 9: 1701-1704.
25. Olney J. W., Labruyere J. and Price M. T. (1989b) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360-1362.
26. Paxinos G. and Watson G. (1984) The Rat Brain in Stereotaxic Coordinates. Academic Press, U.S.A.
27. Ríos C. and Santamaría A. (1991) Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 16: 1139-1143.
28. Russi P., Carla V. and Moroni F. (1989) Indolpyruvic acid administration increases the brain content of kynurenic acid. Biochem. Pharmac. 38: 2405-2409.
29. Russi P., Alesiani M., Lombardi G., Davolio P., Pellicciari R. and Moroni F. (1992) Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem. 59: 2076-2080.
30. Santamaría A. and Ríos C. (1993) MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci. Lett. 159: 51-54.
31. Santamaría A., Altagracia M., Solís F., Kravzov J., Ordaz H., Gonzalez L. and Ríos C. (1994) Kynurenine and probenecid prevent quinolinic acid-induced neurotoxicity in rat corpus striatum. Proc. West. Pharmac. Soc. 37: 29-30.
32. Schwarcz R., Fuxe K., Agnati L. F., Hockfelt T. and Coyle J. T. (1979) Rotational behavior in rats with unilateral striatal kainic acid lesions: a behavioral model for studies on intact dopamine receptors. Brain Res. 170: 485-495.
33. Schwarcz R., Whetsell Jr. W. O. and Mangano R. M. (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219: 316-318.
34. Schwarcz R., Foster A. C., French E. D., Whetsell Jr. W. O. and Köhler C. (1984) Excitotoxic models for neurodegenerative disorders. Life Sci. 35: 19-32.
35. Schwarcz R., Okuno E., White R. J., Bird E. D. and Whetsell W. O. Jr. (1988) 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc. Natn. Acad. Sci. 85: 4079-4081.
36. Siegel S. (1980) Non Parametric Statistics for the Behavioral Sciences. McGraw-Book Company, New York, U.S.A.
37. Smith R. J. and Panico K. A. (1985) Automated analysis of o-phthalaldehyde derivatives of amino acids in physiological fluids by reverse phase high performance liquid chromatography. J. Liquid Chromatogr. 8: 1783-1795.
38. Steel R. G. D. and Torrie J. H. (1980) Principles and Procedures of Statistics. McGraw-Hill Inc., U.S.A.
39. Stone T. W. and Connick J. H. (1985) Quinolinic acid and other kynurenines in the central nervous system. Neuroscience 15: 597-617.
40. Stone T. W. (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmac. Rev. 45: 309-379.
41. Susel Z., Engber T. M. and Chase T. N. (1989) Behavioral evaluation of the anti-excitotoxic properties of MK-801: comparison with neurochemical measurements. Neurosci. Lett. 104: 125-129.
42. Swartz K. J., During M. J., Freese A. and Beal M. F. (1990) Cerebral synthesis and release on kynurenic acid and endogenous antagonist of excitatory amino acid receptors. J. Neurosci. 10: 2965-2973.
43. Taylor C. P. and Vartanian M. G. (1992) Probenecid pretreatment enhances anticonvulsant action of NBQX in mice. Eur. J. Pharmac. 213: 151-153.
44. Traynelis S. F. and Cull-Candy S. G. (1990) Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature 345: 347-350.
45. van der Heyden J. A. M. and Korf J. (1978) Regional levels of GABA in the brain: rapid semiautomated assay and prevention of postmortem increase by 3-mercapto-propionic acid. J. Neurochem. 31: 197-203.
46. Vécsei L., Miller J. M., MacGarvey U. and Beal M. F. (1992a) Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid. Neurodegen. 1: 17-26.
47. Vécsei L., Miller J., MacGarvey U. and Beal M. F. (1992b) Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res. Bull. 28: 233-238.
48. Weiner I. M. (1980) Inhibitors of tubular transport of organic compounds. In: The Pharmacological Basis of Therapeutics (Goodman and Gilman, Eds), pp. 743-746. Pergamon Press, U.S.A.